{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T06:43:14Z","timestamp":1791268994521,"version":"4.1.0"},"reference-count":83,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transplantation Reviews"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1016\/j.trre.2013.06.001","type":"journal-article","created":{"date-parts":[[2013,8,8]],"date-time":"2013-08-08T04:16:46Z","timestamp":1375935406000},"page":"97-107","source":"Crossref","is-referenced-by-count":84,"title":["Review of combination therapy with mTOR inhibitors and tacrolimus minimization after transplantation"],"prefix":"10.1016","volume":"27","author":[{"given":"V. Ram","family":"Peddi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Wiseman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Chavin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Slakey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.trre.2013.06.001_bb0005","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1111\/j.1600-6143.2009.02834.x","article-title":"KDIGO clinical practice guideline for the care of kidney transplant recipients","volume":"9","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group 2201","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2013.06.001_bb0010","doi-asserted-by":"crossref","first-page":"S101","DOI":"10.2215\/CJN.03510807","article-title":"Minimizing immunosuppression, an alternative approach to reducing side effects: objectives and interim result","volume":"3","author":"Srinivas","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.trre.2013.06.001_bb0015","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.1432-2277.2010.01140.x","article-title":"Calcineurin inhibitor sparing regimens using m-target of rapamycin inhibitors: an opportunity to improve cardiovascular risk following kidney transplantation?","volume":"24","author":"Zeier","year":"2011","journal-title":"Transpl Int"},{"key":"10.1016\/j.trre.2013.06.001_bb0020","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1365-2249.2005.02662.x","article-title":"Immunosuppression: towards a logical approach in liver transplantation","volume":"139","author":"Perry","year":"2005","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.trre.2013.06.001_bb0025","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.critrevonc.2005.03.012","article-title":"Immunosuppressive agents in solid organ transplantation: mechanisms of action and therapeutic efficacy","volume":"56","author":"Taylor","year":"2005","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.trre.2013.06.001_bb0030","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1056\/NEJMoa020009","article-title":"The natural history of chronic allograft nephropathy","volume":"349","author":"Nankivell","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trre.2013.06.001_bb0035","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMoa021744","article-title":"Chronic renal failure after transplantation of a nonrenal organ","volume":"349","author":"Ojo","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trre.2013.06.001_bb0040","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1681\/ASN.2008111186","article-title":"The role of the mammalian target of rapamycin (mTOR) in renal disease","volume":"20","author":"Lieberthal","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.trre.2013.06.001_bb0045","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2165\/00003088-200443020-00002","article-title":"Clinical pharmacokinetics of everolimus","volume":"43","author":"Kirchner","year":"2004","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.trre.2013.06.001_bb0050","doi-asserted-by":"crossref","first-page":"219S","DOI":"10.1016\/S0041-1345(03)00222-7","article-title":"Preclinical results of sirolimus treatment in transplant models","volume":"35","author":"Stepkowski","year":"2003","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2013.06.001_bb0055","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.4049\/jimmunol.153.7.3307","article-title":"Rapamycin inhibits production of cytotoxic but not noncytotoxic antibodies and preferentially activates T helper 2 cells that mediate long-term survival of heart allografts in rats","volume":"153","author":"Ferraresso","year":"1994","journal-title":"J Immunol"},{"key":"10.1016\/j.trre.2013.06.001_bb0060","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1016\/j.jhep.2011.06.015","article-title":"m-TOR inhibitors: what role in liver transplantation?","volume":"55","author":"Kawahara","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.trre.2013.06.001_bb0065","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1111\/j.1600-6143.2012.04212.x","article-title":"Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial","volume":"12","author":"De Simone","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2013.06.001_bb0070","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1177\/039139880903200608","article-title":"Decreased acute rejection and improved renal allograft survival using sirolimus and low-dose calcineurin inhibitors without induction therapy","volume":"32","author":"Tsai","year":"2009","journal-title":"Int J Artif Organs"},{"key":"10.1016\/j.trre.2013.06.001_bb0075","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1097\/00007890-199712270-00039","article-title":"Tacrolimus (FK506) and sirolimus (rapamycin) in combination are not antagonistic but produce extended graft survival in cardiac transplantation in the rat","volume":"64","author":"Vu","year":"1997","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2013.06.001_bb0080","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1097\/00007890-200008270-00027","article-title":"Mechanism of the combination immunosuppressive effects of rapamycin with either cyclosporine or tacrolimus","volume":"70","author":"Khanna","year":"2000","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2013.06.001_bb0085","doi-asserted-by":"crossref","first-page":"i12","DOI":"10.1093\/ndt\/gfg1029","article-title":"Pharmacokinetics of tacrolimus-based combination therapies","volume":"18","author":"Undre","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.trre.2013.06.001_bb0090","doi-asserted-by":"crossref","first-page":"489","DOI":"10.2165\/11317240-000000000-00000","article-title":"Pharmacokinetic optimization of immunosuppressive therapy in thoracic transplantation: part II","volume":"48","author":"Monchaud","year":"2009","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.trre.2013.06.001_bb0095","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1016\/j.transproceed.2006.10.092","article-title":"Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus","volume":"38","author":"Kovarik","year":"2006","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2013.06.001_bb0100","series-title":"Zortress (everolimus) tablets for oral use [prescribing information]","author":"Novartis Pharmaceuticals Corporation","year":"2012"},{"key":"10.1016\/j.trre.2013.06.001_bb0105","series-title":"Prograf (tacrolimus) capsules and injection [prescribing information]","author":"Astellas Pharma US, Inc","year":"2012"},{"key":"10.1016\/j.trre.2013.06.001_bb0110","series-title":"Rapamune (sirolimus) oral solution and tablets [prescribing information]","author":"Wyeth Pharmaceuticals","year":"2011"},{"key":"10.1016\/j.trre.2013.06.001_bb0115","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/j.1432-2277.2012.01465.x","article-title":"Everolimus plus early tacrolimus minimization: a phase III, randomized, open-label, multicentre trial in renal transplantation","volume":"25","author":"Langer","year":"2012","journal-title":"Transpl Int"},{"key":"10.1016\/j.trre.2013.06.001_bb0120","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/01.TP.0000101495.22734.07","article-title":"A randomized long-term trial of tacrolimus\/sirolimus versus tacrolimus\/mycophenolate mofetil versus cyclosporine (NEORAL)\/sirolimus in renal transplantation. II. Survival, function, and protocol compliance at 1year","volume":"77","author":"Ciancio","year":"2004","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2013.06.001_bb0125","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1097\/01.tp.0000203894.53714.27","article-title":"A randomized long-term trial of tacrolimus\/sirolimus versus tacrolimums\/mycophenolate versus cyclosporine\/sirolimus in renal transplantation: three-year analysis","volume":"81","author":"Ciancio","year":"2006","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2013.06.001_bb0130","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1111\/j.1600-6143.2005.01064.x","article-title":"Comparison of sirolimus with low-dose tacrolimus versus sirolimus-based calcineurin inhibitor-free regimen in live donor renal transplantation","volume":"5","author":"Hamdy","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2013.06.001_bb0135","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1097\/01.TP.0000121504.69676.5E","article-title":"Comparison of sirolimus-based calcineurin inhibitor-sparing and calcineurin inhibitor-free regimens in cadaveric renal transplantation","volume":"77","author":"Lo","year":"2004","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2013.06.001_bb0140","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1016\/j.transproceed.2012.07.142","article-title":"High incidence of rejection episodes and poor tolerance of sirolimus in a protocol with early steroid withdrawal and calcineurin inhibitor-free maintenance therapy in renal transplantation: experiences of a randomized prospective single-center study","volume":"44","author":"Burkhalter","year":"2012","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2013.06.001_bb0145","doi-asserted-by":"crossref","first-page":"115S","DOI":"10.1016\/S0041-1345(03)00210-0","article-title":"Reduced and standard target concentration tacrolimus with sirolimus in renal allograft recipients","volume":"35","author":"Russ","year":"2003","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2013.06.001_bb0150","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.1399-0012.2004.00116.x","article-title":"Observations regarding the use of sirolimus and tacrolimus in high-risk cadaveric renal transplantation","volume":"18","author":"Lo","year":"2004","journal-title":"Clin Transplant"},{"key":"10.1016\/j.trre.2013.06.001_bb0155","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1097\/TP.0b013e318166927b","article-title":"Multicenter, randomized study of the use of everolimus with tacrolimus after renal transplantation demonstrates its effectiveness","volume":"85","author":"Chan","year":"2008","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2013.06.001_bb0160","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/TP.0b013e3181de1d67","article-title":"Optimal everolimus concentration is associated with risk reduction for acute rejection in de novo renal transplant recipients","volume":"90","author":"Chan","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2013.06.001_bb0165","doi-asserted-by":"crossref","first-page":"4138","DOI":"10.1016\/j.transproceed.2009.08.065","article-title":"Renal function outcomes in kidney transplant recipients after conversion to everolimus-based immunosuppression regimen with CNI reduction or elimination","volume":"41","author":"Cataneo-D\u00e1vila","year":"2009","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2013.06.001_bb0170","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1097\/TP.0b013e3181cbac2d","article-title":"Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction: a multicenter, randomized trial","volume":"89","author":"Gullestad","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2013.06.001_bb0175","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.healun.2011.12.010","article-title":"Improvement in renal function after everolimus introduction and calcineurin inhibitor reduction in maintenance thoracic transplant recipients: the significance of baseline glomerular filtration rate","volume":"31","author":"Arora","year":"2012","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.trre.2013.06.001_bb0180","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1111\/j.1523-1755.2005.00224.x","article-title":"Use of sirolimus and low-dose calcineurin inhibitor in lung transplant recipients with renal impairment: results of a controlled pilot study","volume":"67","author":"Shitrit","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.trre.2013.06.001_bb0185","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1097\/TP.0b013e3181a60431","article-title":"Tacrolimus\/sirolimus versus tacrolimus\/mycophenolate in kidney transplantation: improved 3-year graft and patient survival in recent era","volume":"87","author":"Gralla","year":"2009","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2013.06.001_bb0190","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.transproceed.2004.12.109","article-title":"No-load sirolimus with tacrolimus and steroids is safe and effective in renal transplantation","volume":"37","author":"Tellis","year":"2005","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2013.06.001_bb0195","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1111\/j.1399-0012.2010.01353.x","article-title":"Albuminuria after renal transplantation: maintenance with sirolimus\/low-dose tacrolimus vs. mycophenolate mofetil\/high-dose tacrolimus","volume":"25","author":"Miles","year":"2011","journal-title":"Clin Transplant"},{"key":"10.1016\/j.trre.2013.06.001_bb0200","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1016\/j.transproceed.2008.05.047","article-title":"Excellent long-term results in de novo renal transplant recipients treated with proliferation signal inhibitors and reduced calcineurin inhibitors exposure","volume":"40","author":"Carmellini","year":"2008","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2013.06.001_bb0205","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.healun.2006.01.004","article-title":"Early renal benefit of rapamycin combined with reduced calcineurin inhibitor dose in pediatric heart transplantation patients","volume":"25","author":"Balfour","year":"2006","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.trre.2013.06.001_bb0210","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/j.1399-0012.2007.00686.x","article-title":"Comparison of sirolimus and everolimus in their effects on blood lipid profiles and haematological parameters in heart transplant recipients","volume":"21","author":"Tenderich","year":"2007","journal-title":"Clin Transplant"},{"key":"10.1016\/j.trre.2013.06.001_bb0215","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1111\/j.1399-3046.2004.00193.x","article-title":"Improvement in renal function and rejection control in pediatric liver transplant recipients with the introduction of sirolimus","volume":"8","author":"Casas-Melley","year":"2004","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.trre.2013.06.001_bb0220","doi-asserted-by":"crossref","first-page":"3513","DOI":"10.1016\/j.transproceed.2010.08.043","article-title":"Low-dose calcineurin inhibitor regimen combined with mammalian target of rapamycin inhibitors preserves kidney functions in renal transplant recipients without allograft nephropathy","volume":"42","author":"Kacar","year":"2010","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2013.06.001_bb0225","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1097\/TP.0b013e31825b411c","article-title":"A comprehensive review of everolimus clinical reports: a new mammalian target of rapamycin inhibitor","volume":"94","author":"Gurk-Turner","year":"2012","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2013.06.001_bb0230","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.2165\/11319260-000000000-00000","article-title":"Immunosuppressive drugs in kidney transplantation: impact on patient survival, and incidence of cardiovascular disease, malignancy and infection","volume":"69","author":"Marc\u00e9n","year":"2009","journal-title":"Drugs"},{"key":"10.1016\/j.trre.2013.06.001_bb0235","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1053\/j.ajkd.2010.10.048","article-title":"Hypertension after kidney transplant","volume":"57","author":"Mangray","year":"2011","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.trre.2013.06.001_bb0240","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1600-6135.2004.0355.x","article-title":"Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative","volume":"4","author":"Kasiske","year":"2004","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2013.06.001_bb0245","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.atherosclerosis.2007.09.019","article-title":"Prevention of atherosclerosis by the mTOR inhibitor everolimus in LDLR\u2212\/\u2212 mice despite severe hypercholesterolemia","volume":"198","author":"Mueller","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.trre.2013.06.001_bb0250","doi-asserted-by":"crossref","first-page":"H1646","DOI":"10.1152\/ajpheart.00492.2009","article-title":"Sirolimus inhibits endogenous cholesterol synthesis induced by inflammatory stress in human vascular smooth muscle cells","volume":"298","author":"Ma","year":"2010","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.trre.2013.06.001_bb0255","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/j.1600-6143.2007.02101.x","article-title":"Patient survival and cardiovascular risk after kidney transplantation: the challenge of diabetes","volume":"8","author":"Cosio","year":"2008","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2013.06.001_bb0260","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1111\/j.1600-6143.2007.01749.x","article-title":"Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus","volume":"7","author":"Vincenti","year":"2007","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2013.06.001_bb0265","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1007\/BF03343761","article-title":"The metabolic effects of cyclosporin and tacrolimus","volume":"23","author":"Marchetti","year":"2000","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.trre.2013.06.001_bb0270","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1681\/ASN.2007111202","article-title":"Sirolimus is associated with new-onset diabetes in kidney transplant recipients","volume":"19","author":"Johnston","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.trre.2013.06.001_bb0275","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/j.1600-6143.2004.00389.x","article-title":"Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies","volume":"4","author":"Vitko","year":"2004","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2013.06.001_bb0280","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1016\/j.transproceed.2004.09.026","article-title":"Graft function, cardiovascular risk factors, and sex hormones in renal transplant recipients on an immunosuppressive regimen of everolimus, reduced dose of cyclosporine, and basiliximab","volume":"37","author":"Kr\u00e4mer","year":"2005","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2013.06.001_bb0285","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1053\/j.ajkd.2009.06.031","article-title":"Proteinuria in kidney transplant recipients: prevalence, prognosis, and evidence-based management","volume":"54","author":"Knoll","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.trre.2013.06.001_bb0290","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1681\/ASN.2008091005","article-title":"Significance and management of proteinuria in kidney transplant recipients","volume":"20","author":"Amer","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.trre.2013.06.001_bb0295","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(10)62318-5","article-title":"Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial","volume":"377","author":"Budde","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.trre.2013.06.001_bb0300","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/j.1432-2277.2008.00801.x","article-title":"Factors associated with proteinuria in renal transplant recipients treated with sirolimus","volume":"22","author":"Liew","year":"2009","journal-title":"Transpl Int"},{"key":"10.1016\/j.trre.2013.06.001_bb0305","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1111\/j.1600-6143.2010.03129.x","article-title":"Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients","volume":"10","author":"Tedesco Silva","year":"2010","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2013.06.001_bb0310","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1111\/j.1432-2277.2012.01500.x","article-title":"Proteinuria after kidney transplantation","volume":"25","author":"Ponticelli","year":"2012","journal-title":"Transpl Int"},{"key":"10.1016\/j.trre.2013.06.001_bb0315","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/jmv.10450","article-title":"Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40","volume":"71","author":"Knowles","year":"2003","journal-title":"J Med Virol"},{"key":"10.1016\/j.trre.2013.06.001_bb0320","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/infdis\/147.4.676","article-title":"Persistence of DNA sequences of BK virus and JC virus in normal human tissues and in diseased tissues","volume":"147","author":"Chesters","year":"1983","journal-title":"J Infect Dis"},{"key":"10.1016\/j.trre.2013.06.001_bb0325","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/rmv.1733","article-title":"Effect of maintenance immunosuppressive drugs on virus pathobiology: evidence and potential mechanisms","volume":"23","author":"Brennan","year":"2013","journal-title":"Rev Med Virol"},{"key":"10.1016\/j.trre.2013.06.001_bb0330","doi-asserted-by":"crossref","first-page":"86","DOI":"10.12659\/AOT.882640","article-title":"BK virus replication following kidney transplant: does the choice of immunosuppressive regimen influence outcomes?","volume":"17","author":"Acott","year":"2012","journal-title":"Ann Transplant"},{"key":"10.1016\/j.trre.2013.06.001_bb0335","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1097\/TP.0b013e31825a505d","article-title":"Factors influencing viral clearing and renal function during polyomavirus BK-associated nephropathy after renal transplantation","volume":"94","author":"Schwarz","year":"2012","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2013.06.001_bb0340","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1523-1755.2004.00735.x","article-title":"Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival","volume":"66","author":"Sagedal","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.trre.2013.06.001_bb0345","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1111\/j.1600-6143.2011.03674.x","article-title":"Cytomegalovirus incidence between everolimus versus mycophenolate in de novo renal transplants: pooled analysis of three clinical trials","volume":"11","author":"Brennan","year":"2011","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2013.06.001_bb0350","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/tid.12007","article-title":"Everolimus is associated with a reduced incidence of cytomegalovirus infection following de novo cardiac transplantation","volume":"15","author":"Kobashigawa","year":"2013","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.trre.2013.06.001_bb0355","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/j.1432-2277.2003.tb00343.x","article-title":"A single-centre experience of post-renal transplant lymphoproliferative disorder","volume":"16","author":"Herzig","year":"2003","journal-title":"Transpl Int"},{"key":"10.1016\/j.trre.2013.06.001_bb0360","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1046\/j.1600-6143.2003.00325.x","article-title":"Lymphomas after solid organ transplantation: a collaborative transplant study report","volume":"4","author":"Opelz","year":"2004","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2013.06.001_bb0365","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1016\/j.transproceed.2010.05.162","article-title":"Targeting risk factors for impaired wound healing and wound complications after kidney transplantation","volume":"42","author":"Roine","year":"2010","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2013.06.001_bb0370","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.critrevonc.2004.11.010","article-title":"Cancer incidence after immunosuppressive treatment following kidney transplantation","volume":"56","author":"Andr\u00e9s","year":"2005","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.trre.2013.06.001_bb0375","series-title":"USRDS 2012 annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States","author":"US Renal Data System","year":"2012"},{"key":"10.1016\/j.trre.2013.06.001_bb0380","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1097\/00007890-200405150-00002","article-title":"Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice","volume":"77","author":"Koehl","year":"2004","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2013.06.001_bb0385","doi-asserted-by":"crossref","first-page":"i36","DOI":"10.1093\/ndt\/gfm090","article-title":"Use of proliferation signal inhibitors in the management of post-transplant malignancies\u2013clinical guidance","volume":"22","author":"Campistol","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.trre.2013.06.001_bb0390","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1097\/00007890-200205270-00008","article-title":"Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy","volume":"73","author":"Luan","year":"2002","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2013.06.001_bb0395","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/j.1399-0012.2004.00188.x","article-title":"Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies","volume":"18","author":"Mathew","year":"2004","journal-title":"Clin Transplant"},{"key":"10.1016\/j.trre.2013.06.001_bb0400","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1097\/01.TP.0000184006.43152.8D","article-title":"Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies","volume":"80","author":"Kauffman","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2013.06.001_bb0405","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1056\/NEJMoa1204166","article-title":"Sirolimus and secondary skin-cancer prevention in kidney transplantation","volume":"367","author":"Euvrard","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trre.2013.06.001_bb0410","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/j.1600-6143.2012.04334.x","article-title":"The effect of everolimus versus mycophenolate upon proteinuria following kidney transplant and relationship to graft outcomes","volume":"13","author":"Wiseman","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2013.06.001_bb0415","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/ctr.12045","article-title":"Association of clinical events with everolimus exposure in kidney transplant patients receiving reduced cyclosporine","volume":"27","author":"Shihab","year":"2013","journal-title":"Clin Transplant"}],"container-title":["Transplantation Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0955470X13000827?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0955470X13000827?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T05:00:55Z","timestamp":1715835655000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0955470X13000827"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":83,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["S0955470X13000827"],"URL":"https:\/\/doi.org\/10.1016\/j.trre.2013.06.001","relation":{},"ISSN":["0955-470X"],"issn-type":[{"value":"0955-470X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10]]}}}